Clinical relevance of maximal inspiratory pressure: determination in COPD exacerbation by Tudorache, Voicu et al.
© 2010 Tudorache et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Chronic Obstructive Pulmonary Disease 2010: 5 119–123
International Journal of Chronic Obstructive Pulmonary Disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
119
OrIgInAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
Clinical relevance of maximal inspiratory  
pressure: determination in COPD exacerbation
Voicu Tudorache1 
Cristian Oancea1 
Ovidiu Fira Mlădinescu2
1Department of Pneumology, 
2Department of Pathophysiology, 
Victor Babeş University of Medicine 
and Pharmacy, Timişoara, Romania
Correspondence: Voicu Tudorache
Department of Pneumology, Victor 
Babeş University of Medicine and 
Pharmacy, eftimie Murgu sq, no 2, 
300041, Timişoara, Romania
email voicu.tudorache@yahoo.com
Abstract: Muscle dysfunction represents a pathophysiological feature of chronic obstructive 
pulmonary disease (COPD). Muscle impairment contributes to decreased effort capacity in these 
patients at least in the same proportion as pulmonary function limitation. Maximal inspiratory 
pressure (MIP) is a reliable, noninvasive parameter for assessing the respiratory muscle capac-
ity. The aim of the present study was to determine the role of MIP in effort capacity decrease in 
COPD patients. MIP was measured in 121 COPD patients without hyperinflation (RV , 150%) 
together with the following investigations: body plethysmography, body impedance analysis, 
dynamometry, 6-minute walking test (6MWT), determination of SaO2 and serum levels of highly 
sensitive C-reactive protein (hsCRP). MIP (kPa) was significantly decreased in moderate-severe 
stages (6.19 ± 2.42, COPD II; 5.35 ± 2.49, COPD III; 4.56 ± 1.98, COPD IV vs 7.90 ± 2.61 in 
controls,  P , 0.001), whereas the muscle force assessed by dynamometry was decreased only 
in advanced stages of disease (0.47 ± 0.12, COPD III; 0.41 ± 0.07, COPD IV vs 0.71 ± 0.16 
in controls,  P , 0.001). The values of MIP correlated (r = 0.53, P = 0.0003) with the distance 
walked in 6MWT. MIP may provide additive information concerning the general profile of 
muscle dysfunction in COPD patients.
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Introduction
Chronic obstructive pulmonary disease (COPD) is today considered a disease 
with multiple systemic pathological components. Muscular dysfunction represents 
one of these components, and in COPD patients it is responsible for the decrease 
in effort capacity at least in the same manner as respiratory function limitation; 
moreover in time it exceeds the component generated by pulmonary dysfunction 
due to the impact of this dysfunction on effort capacity and other components (eg, 
quality of life).1,2
In the context of global muscular dysfunction, inspiratory muscle function is 
frequently affected. Inspiratory muscle dysfunction results from the interference of 
thoracic geometry changes with systemic inflammatory factors and/or the structural 
alteration of these muscles. Inspiratory muscle dysfunction apparently does not limit 
resting ventilatory capacity, but seems to contribute to dyspnea, decrease in effort 
capacity, and respiratory failure during exacerbation (E-COPD).3,4,5
Composite indexes like BODE (Body mass index [BMI], Obstruction, Dyspnea, 
Exercise capacity) that incorporate some parameters related to muscles (BMI 6-minute 
walking test [6MWT]), provide a global perspective regarding muscular capacity.6International Journal of Chronic Obstructive Pulmonary Disease 2010: 5 submit your manuscript | www.dovepress.com
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The analysis of certain symptoms that suggest decreased 
respiratory muscle function, such as vital capacity decrease 
without any explanation, retention of CO2 without severe 
obstruction of respiratory airwaves, dyspnea, orthopnea, or 
dyspnea during activities of daily living (ADL), tachypnea, 
paradoxical movement of the thoracic–abdominal wall, cough 
and recurrent infections, difficulties in speaking, etc, is more 
or less specific and indirect at the same time.3,7
Decrease in inspiratory muscle function, especially of the 
diaphragm muscle, may explain not only the symptomatol-
ogy described above, but also the fact that it represents an 
important prediction factor for the survival rate in COPD 
patients.6,8,9
This explains why more and more specific and reliable 
instruments and methods for the functional assessment of 
these muscles are searched.
One of these methods is represented by the assessment of 
maximal inspiratory pressure (MIP) and maximal expiratory 
pressure (MEP). This noninvasive method is reliable, easy 
to perform and well accepted by patients, and consequently 
easy to apply in current clinical pratice.10,11
Although muscle wasting is currently accepted, the ques-
tions regarding the clinical relevance of MIP determination 
arises and it is the main goal of our research. The second 
goal of the study was to investigate the correlation degree 
of MIP values obtained from patients, with other parameters 
that interfere with muscle dysfunction.
Material and methods
One hundred twenty-one COPD patients in the 10th day of 
treatment for exacerbation were compared to the reference 
group consisting of 31 healthy nonsmokers individuals. The 
study protocol was approved by the hospital ethics committee 
and patients gave their written consent. The patients with 
stage 2–3 E-COPD according to Anthonisen’s classification 
had mild-severe disease (stage III–IV Global Initiative for 
Chronic Obstructive Lung Disease [GOLD]),12 were smokers, 
and during their admission in the hospital received antibiot-
ics and also systemic corticotherapy treatment for at least 10 
days. In Table 1 other features of the patients are presented 
compared to the E-COPD group.
Exclusion criteria were represented by: myopathy, sig-
nificant hyperinflation (RV $ 150%), severe comorbidities 
(any form of cancer, diffuse pulmonary fibrosis or extended 
fibrotic sequelae, heart failure, advanced ischemic heart 
disease, diabetes mellitus).
Patients from the COPD group were not included in a 
pulmonary rehabilitation program. It was affirmed that all 
patients took the medication prescribed by the pneumology 
specialist in ambulatory care.
The subjects followed a certain protocol for investi-
gations:
–  Complete clinical evaluation
–  Determination of the muscular force of the dominant 
superior limb (dynamometry)
–  Determination of body composition (body impedance 
analysis – BIA) and of body mass index (BMI)
–  Spirometry and body plethismography
–  Determination of MIP and MEP
–  6-minute walking test (6MWT)
–  dyspnea evaluation (Borg scale)
–  systemic inflammation evaluation by measuring the 
hypersensitive fraction of C-reactive protein (hsCRP).
A spirometer (Jaeger, Wuerzburg, Germany) with shutter 
module for analysis of muscular respiratory pressures was 
used. The obtained values were expressed as percentages 
from ideal values. The force of respiratory muscles may be 
evaluated using the static measurements (MIP, MEP), or it 
may result from dynamic maneuvers (MVV – voluntary 
maximal ventilation).
MIP represents the highest subatmospheric pressure that 
can be generated during an inspiration against a blocked 
airway (Muller maneuver). MEP is the highest pressure 
that can be achieved during a high expiratory effort against 
a blocked airway (Valsalva maneuver). The method is usu-
ally used by starting the maneuver from the residual volume 
for MIP determination and from the maximal capacity for 
MEP determination. There are just a few contraindications 
for these exploratory maneuvers: aneurysm, uncontrolled 
hypertension, urinary infection, recent abdominal or thoracic 
surgery.
The subjects underwent between three and five maximal 
acceptable and reproducible maneuvers (with differences of 
Table 1 Characteristics of patients included in the study
Control 
group 
(sedentary-healthy)
E-COPD 
(hospitalized 
pts)
number 31 121
Male/Female 26/5 109/12
Age (years) 54 ± 9 60 ± 12
smoking state (pack-year) nonsmokers 30 ± 7 
FeV1 (L/s) 2.9 ± 0.31 1.27 ± 0.58
FeV1 (% pred) 96.76 ± 10.44 42.46 ± 19.45
systemic corticotherapy Any Yes*
Note: *32 mg methylprednisolone/day for 10 days with decrease in maximum 2 
weeks.
Abbreviation: FeV1, forced expiratory volume in one second.International Journal of Chronic Obstructive Pulmonary Disease 2010: 5 submit your manuscript | www.dovepress.com
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3%–9% between values). For the statistical evaluation, the 
maximal value obtained from these successive trials was 
taken into consideration. An approximate one minute interval 
was permitted between consecutive efforts.
The technique used followed the principles of Black 
and Hyatt. A minimal leak of air (shutter module) should be 
used in order to prevent the blocking of the epiglottis. This 
minimal leak has no influence on recording measurements. 
The inspiratory or expiratory effort has to be sustained for a 
minimum of one second.
The 6MWT was performed according to the American 
Thoracic Society and the European Respiratory Society 
(ATS/ERS) standard on a 30-m long and 1.5-m wide, flat 
corridor inside the hospital. The patients were asked to 
walk the maximal distance they could for 6 minutes. They 
were monitored by a doctor who assisted them, periodically 
encouraged them, and informed them about the remaining 
time and the possibility that some adverse clinical signs might 
appear. O2 saturation was assessed using a Nonin (Onys, 
USA) pulse oximeter and was recorded at 3 minutes at the 
beginning of the testing and at 6 minutes at the end of the 
testing. Cardiac parameters (blood pressure [BP] and heart 
rate [HR]) were continuously monitored during the test and 
the dyspnea score on the Borg scale was also assessed. The 
test was performed twice at an interval of 60 minutes and 
we chose the best value.
Hand muscle strength was recorded with a dynamometer 
(Dynatest, Jungingen, Germany). The record was achieved 
after the following procedure: the subject takes the dyna-
mometer in his hand and squeezes it as hard as possible, 
without further movement. Two recordings are required and 
only the highest values obtained on the pressure scale of the 
dynamometer measured in kilograms force were taken into 
consideration. The procedure was performed with the domi-
nant hand. Obtained values are expressed in kgF.
In order to determine body composition a 310e Bio-
dynamics impedance meter was used (Body Composition 
Analyzer, USA), that is able to provide data concerning: 
lean body weight (LBW; total weight without fat); fat body 
weight (FBW, mass of body fat); and percentage of body fat 
(%BF). Although FBW and %BF may vary (heart disease, 
salt diet, etc), LBW represents a more stable and specific 
parameter than BMI or anthropometric parameters in assess-
ing muscle mass.
hsCRP is a parameter that reflects systemic inflammation, 
normal values being # 6 IU/L.13
Statistical analysis and graphic representation of the data 
were performed using the software programs Microsoft Excel 
2003 (Microsoft Corporation, Redmond, WA, USA) and 
GraphPad Prism 4 (GraphPad Software, La Jolla, CA, USA). 
All presented data are expressed as mean ± standard 
deviation.
Statistical comparison of the data from all groups was 
performed by means of analysis of variance tests (ANOVA) 
followed by post-hoc analysis using the Dunnett multiple 
comparisons test. The power link between certain studied 
variables was assessed using the Pearson’s correlation 
coefficient. Statistical significance was considered when  
P , 0.05. We used the scale of assessment by Beaglehole 
(1997), regardless of the purpose of the association: strong 
(r . 0.70), moderate (r between 0.40–0.70), weak (r between 
0.20–0.40), and absent (r , 0.20.)
Results
The results of the investigations according to each stage 
of COPD, with the significant differences compared to the 
control group, are presented in Table 2.
MIP (kPa) was found to be significantly decreased in 
mild-severe stages of COPD. Muscle force (kgf) assessed by 
dynamometry was found to be decreased only in advanced 
Table 2 The relationship between different variables and the severity of COPD
Control 31  
patients
COPD I 4  
patients
COPD II 34  
patients
COPD III 33 
patients
COPD IV 50 
patients
MIP (kPa) 7.9 ± 2.6 7.74 ± 3.99 6.19 ± 2.42* 5.35 ± 2.49*** 4.56 ± 1.98*** P , 0.001
MeP (kPa) 10.84 ± 2.76 10.07 ± 3.6 8.64 ± 2.88* 8.32 ± 3.19** 7.9 ± 3.14*** P , 0.01
Dynamometry (kgF) 0.71 ± 0.16 0.55 ± 0.13 0.53 ± 0.15*** 0.47 ± 0.12*** 0.41 ± 0.07*** P , 0.05
LBW (kg) 66.2 ± 12 58.6 ± 10.11 57.16 ± 9.69** 56.89 ± 13.11** 54.49 ± 9.79*** P , 0.001
6MWT (m) 544 ± 87 515 ± 59 472 ± 82* 350 ± 99*** 84 ± 129 *** P , 0.001
saO2 (%) 97 ± 2 97 ± 1 96 ± 3 94 ± 2** 89 ± 5*** P , 0.001
FeV1 (L/s) 2.90 ± 0.25** 2.49 ± 0.24 1.93 ± 0.27*** 1.15 ± 0.17*** 0.74 ± 0.26*** P = 0.036
FeV1 (% pred) 96.76 ± 8.66* 83.6 ± 8.39 64.34 ± 9.21*** 38.65 ± 5.95*** 24.84 ± 8.98***
Note: *P , 0.05 vs control, **P , 0.01 vs control, ***P , 0.001 vs control.
Abbreviations: MIP, maximal inspiratory pressure; MeP, maximal expiratory pressure; LBW, lean body weight; 6 MWT, 6 minutes walking time; FeV1, forced expiratory 
volume in one second.International Journal of Chronic Obstructive Pulmonary Disease 2010: 5 submit your manuscript | www.dovepress.com
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stages of the disease. MIP values were well correlated 
(r = 0.53, P = 0.0003) with 6 MWT (Figure 1). This final test 
was also found to be correlated (r = −0.68, P = 0.0004) with 
CRPhs values. No significant correlation could be noticed in 
the case of the relation between MIP and CRPhs.
We also found a mild decreased association between forced 
expiratory volume in one second (FEV1) and 6MWT.
Discussion
Hospitalizations caused by E-COPD are responsible for a 
state of prolonged physical inactivity due to a variable degree 
of muscle wasting. Decreased muscle strength induced by 
E-COPD is due to metabolic and nutritional dysfunctions, 
oxidative stress, and an amplification of the inflammatory 
status. Bed rest and systemic glucocorticoid treatment also 
contribute to decreased muscle strength.
This explains that in the 6MWT test only 35% of the 
patients with stage III E-COPD had finished the test and only 
11% of the patients with stage IV E-COPD have performed 
this test, showing a weak to moderate association between 
MIP and 6MWT in these stages.
Information obtained after testing the peripheral and 
respiratory muscles may be helpful in establishing the type 
of physical training. Free muscle mass (LBW) is inversely 
correlated with disease severity: stage IV patients obtained 
the lowest values (P , 0.001), which means a very reduce 
muscular mass.
Pulmonary function (as reflected by FEV1) diminishes 
once with the beginning of E-COPD and is recovering 
slowly (≅8.6%) 2 months later, one of the factors respon-
sible for monitoring is very likely MIP (∆ = 1.65 kPa, 
P = 0.003).
A moderate degree of systemic inflammation is today 
considered a primary factor in the development of COPD, 
cachexia/muscle wasting, and cardiovascular diseases. 
hsCRP, as an inflammatory marker, was found to have 
increased in the stable phase of COPD and even more dur-
ing exacerbation.
The difference between acute and stable phases is not 
significant (P = 0.41) because many patients were in an 
advanced stage of disease and 40% of them had associated 
cardiovascular diseases.
No significant correlations between MIP and hsCRP were 
found. This could be due to the fact that hsCRP is a global 
marker of inflammation, not as specific for muscle wasting 
as tumor necrosis factor or interleukin-6.
Study limitations
Comparison of parameters in the same patient was not per-
formed in acute or stable phases, although the groups could 
be compared in terms of disease stage, age, sex, tobacco use 
status, etc. There was a numerical difference between groups 
(E-COPD and control group). It was difficult to include more 
patients in the control group with similar demographic data to 
those included in the study group (healthy patients with no other 
pathologies that influence the accuracy of the control group).
Contributions of our study
Correlation of MIP with other parameters (respiratory, 
muscular, inflammatory) in E-COPD and stable COPD.
Conclusions
Respiratory muscles fatigue is increased during E-COPD and 
a reverse correlation between MIP and the severity of COPD 
MIP (kPa) MIP (kPa)
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Figure 1 Different correlation between MIP and 6MWT and between MIP and FeV1.
Abbreviations: FeV1, forced expiratory volume in one second; MIP, maximal inspiratory pressure; 6MWT, 6-minute walk test.International Journal of COPD
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was observed, as well as a direct correlation between MIP 
and FEV1. There is a significant correlation between MIP 
and effort capacity (6MWT) similar to the relation between 
peripheral muscles forces and the 6MWT.
Together with other markers, MIP and MEP represent 
markers for assessing the degree of respiratory muscle dys-
function. These parameters can be useful for the diagnosis, 
follow up, and prognosis of patients included in respiratory 
rehabilitation programs, but also in other respiratory or mus-
cle pathologies or in healthy subjects (such as athletes).
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